Amycretin at a glance
| Detail | What the sources say |
|---|---|
| Developer | Novo Nordisk |
| How it works | One molecule activating GLP-1 and amylin receptors |
| Forms studied | Injection under the skin and tablet |
| Stage | Injection: phase 3 (AMAZE, from 2026); tablet: earlier phases |
| Other name | Zenagamtide (Novo Nordisk, 2026) |
| Approved? | No, as of the update date |
From the sources to the app
| What the sources say | What PepLabo does with it |
|---|---|
| Amycretin is studied both as an injection and as a tablet [1]. | PepLabo records either form: a vial or pen with units and sites, or a tablet pack. |
| No approved label exists, so there is no official schedule or storage rule. | PepLabo fills in nothing; every amount and schedule comes from you or your study team. |
| The phase 3 AMAZE 1 trial is registered on ClinicalTrials.gov [3]. | The library entry shows the status with sources and dates. |
What PepLabo does and does not do
| PepLabo does | PepLabo does not |
|---|---|
| Record each dose with the date, time and amount you enter, and the site for injections | Suggest a dose, a schedule change or a medicine |
| Remind you 15 minutes before, at the dose time, and 30 minutes after a missed dose | Tell you what to do after a missed dose; the leaflet and your prescriber do |
| Put check-ins, weight and doses on one timeline | Interpret symptoms or judge progress |
| Keep your records on your phone, with no account needed to track | Use analytics, advertising or tracking SDKs, or write to Apple Health |
| Create a PDF of your dose log for your clinician (Pro) | Replace your clinician or pharmacist |
